Quarterly Earnings

As Vontier accelerates its push into the connected mobility economy, new CPO Denice Biocca brings a playbook for transformation forged at GE and GE Vernova.

With promising Phase 2 data for its novel peptide therapies, Sapience Therapeutics is engaging investors, signaling a critical push for future growth.

Investors watch Gibson Energy closely as it prepares for its Q1 results amid mixed performance, strategic acquisitions, and a changing energy landscape.

As NW Natural Holdings sets its Q1 2026 earnings call, investors watch to see if its diversification strategy can sustain last year's record growth.

Citi Wealth advises investors to anchor in quality U.S. equities, short-term bonds, and gold amid rising volatility fueled by global shocks and inflation.

The employee-owned Colorado bank increased its shareholder payout, reflecting robust financial health and strategic gains in a changing banking landscape.

As Black Diamond readies its Q1 2026 report, investors eye gains from a booming energy market and the strategic expansion of its LodgeLink platform.

The frac sand supplier's special dividend highlights a strong balance sheet and a dual-market strategy, but how does it stack up in a competitive field?

Mobile game maker DarkIris pivots to an AI-first strategy, launching an R&D hub in Singapore to build a pan-entertainment AGI content platform.

Enterprise Products Partners raises its distribution and buys back shares, showcasing financial strength ahead of key industry and earnings forecasts.

As Crocs sets its Q1 earnings call, all eyes are on the struggling HEYDUDE brand, contrasting with the core brand's strong international performance.

China's EdTech giant TAL is set to report Q4 earnings. Investors are watching closely to see if its pivot to AI and smart devices is a winning strategy.

As Option Care Health preps its Q1 results, investors watch if it can seize market share from a retreating rival while navigating major biosimilar headwinds.

ADP's latest dividend declaration highlights its financial strength and commitment to shareholders, cementing its status as a reliable income-generating stock.

With stellar trial data for its cholesterol drug obicetrapib, NewAmsterdam Pharma faces investors as it navigates a competitive market and awaits key results.

As Cincinnati Financial preps its Q1 2026 results, we dive into the key metrics and industry trends that will define its performance and market reaction.

Beasley Broadcast Group reports a staggering $190M Q4 loss after a massive asset write-down, but a major debt cut and digital growth signal a fight for survival.

The Norwegian tech firm is shifting its business model with a new platform designed to tame complex, multi-vendor environments and drive recurring revenue.

With a massive $750M boost to its share buyback, Nutanix underscores its financial strength and bets on its future in hybrid multicloud and enterprise AI.

The revolving sushi chain posts strong sales and narrows losses, proving its automation and expansion strategy is paying off despite economic pressures.